Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Hoffmann-La Roche
Cellectar Biosciences, Inc.
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Massachusetts General Hospital
University of California, San Francisco
Xijing Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Washington University School of Medicine
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Nuvation Bio Inc.
Xennials Therapeutics Australia Pty Ltd
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Emory University
Shenzhen BinDeBio Ltd.
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
Chang Gung Memorial Hospital
AHS Cancer Control Alberta
Chinese PLA General Hospital
Laboratorio Elea Phoenix S.A.
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Envita Medical Center, Inc.
Thallion Pharmaceuticals